P332 GLUCOSAMINE SULFATE IMPROVES QUALITY OF LIFE OF KNEE OSTEOARTHRITIS PATIENTS IN THE GLUCOSAMINE UNUM IN DIE EFFICACY (GUIDE) TRIAL  by Herrero-Beaumont, G. & Branco, J.
S180 Poster Presentations
Results: 41 subjects have completed baseline assessments
and started the training intervention (Age: 65±8 years, BMI:
33.1±6.8kg/m2, Total WOMAC Score: 33±15). Of those, 17
have completed the training intervention. Due to imaging artifact
in the medial compartment, articular cartilage from 14 medial
tibias was segmented. All lateral tibias were included. There was
no significant difference between groups for cartilage thickness
as shown in the table, or any other clinical variables at baseline.
However, medial cartilage volume (P= 0.039) was significantly
lower in the sham group; and lateral denuded area (P=0.02) was
significantly lower in the PRT group at baseline.
Cartilage thickness (P=0.334 MT, P=0.445 LT), volume (P=0.419
MT, P=0.699 LT) and denuded area (P=0.739 MT, P=0.563 LT)
did not change significantly following the training intervention.
Overall strength increased significantly in the PRT group com-
pared to the sham group following the training intervention.
Conclusions: These interim results suggest cartilage thickness,
volume and denuded area were not significantly different be-
tween groups following the training intervention. Overall muscle
strength increased significantly in the PRT group compared to
the sham group over time. Completion of the full complement
of subjects in this ongoing trial will allow further analysis of the
relationship between anabolic exercise and cartilage morphology
in OA.
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Purpose: The GUIDE trial showed the efficacy of the prescrip-
tion glucosamine sulfate formulation on the symptoms of knee
osteoarthritis (Arthritis Rheum 2005;52, 9 Suppl:1203). The aim
of the present study was to assess its effects on Quality of Life
in the GUIDE patient cohort.
Methods: GUIDE was a multicenter, prospective, randomised,
double-blind, parallel-group trial. Patients with knee osteoarthritis
(ACR criteria) received double-dummy oral glucosamine sulfate
soluble powder 1500mg once-a-day, or acetaminophen 1000mg
tablets t.i.d., or placebo for 6 months. Quality of Life was as-
sessed by the SF-36 questionnaire in 296 patients at random-
ization and repeated after 6 months. The primary analysis was
conducted on the changes in the SF-36 Mental Component
Score (MCS, assessing the domains Mental Health, Role Emo-
tional, Social Functioning) and Physical Component Score (PCS,
with domains Bodily Pain, Role Physical, Physical Functioning,
Vitality, General Health, the latter two being included also in the
calculation of the MCS). Changes in each domain were sec-
ondary endpoints. GLM-ANOVA was used with the Dunnet’s test
adjusting for the comparisons of each active vs placebo, in ITT
by the LOCF approach. Effect sizes vs placebo were calculated
as the difference between mean changes standardized on the
pooled SD. The Pearson test assessed the correlation between
the changes in the SF-36 and those in the previously reported
primary (Lequesne index) and secondary (WOMAC index) symp-
tom outcomes in the trial.
P332 – Table 1
Placebo N=96 Acetaminophen N=100 Glucosamine Sulfate N=100
Baseline  6 months Baseline  6 months Baseline  6 months
SF-36 PCS (mean±SD) 33.3±8.3 1.7±10.3 34.2±9.0 4.2±9.1 32.7±9.3 6.7±10.4*
SF-36 MCS (mean±SD) 53.3±11.4 0.7±11.0 50.0±13.2 0.3±11.8 50.9±13.0 0.7±10.6
*P=0.001 vs Placebo: Difference=5.0 (95% CI: 1.9 to 8.2). Effect Size=0.49 (0.20 to 0.77)
Results: Glucosamine sulfate showed an improvement in all
PCS domains of the SF-36, that was significant vs placebo
for Bodily Pain (P=0.014), Role Physical (P=0.006) and Gen-
eral Health (P=0.031). The difference on the aggregate PCS
was therefore highly significant, with a good effect size (Table
1). There were no significant improvements in the MCS, thus
excluding direct psychological effects. Acetaminophen was not
significantly different from placebo in any of the analyses.
There was a highly significant correlation (P<0.01) between the
improvements in the SF-36 PCS and those previously reported
in the Lequesne index (r =0.58) and WOMAC total (r =0.56), pain
(r =0.51) and function (r =0.56) scales, respectively.
Conclusions: Treatment for 6 months with glucosamine sulfate
1500mg once-a-day improves Quality of Life in knee osteoarthri-
tis by favorably affecting the physical components of well-being,
in a way that is highly correlated with its efficacy on pain and
function as assessed by disease specific measures.
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Purpose: Rapidly destructive osteoarthritis of the hip (RDA) is
an uncommon form of hip OA that is seen mostly in elderly
postmenopausal women. Recent discovery of subchondral insuf-
ficiency fracture that precedes destruction of the femoral head
suggests a role for ostopenia during rapid destruction of the hip
joint. The aim of our work was to compare the bone mineral
density (BMD) between patients with rapidly destructive hip OA
(RDA) and slowly progressive hip OA.
Methods: This prospective cross sectional case-control study
was conducted in 26 patients with RDA. Patients were recruited
from our institution between 2000 and 2006. RAD was defined
by the following criteria: severe hip pain; annual rate of joint
space loss >2 mm; erythrocyte sedimentation rate <20 mm/1st
h. MRI of the hip was performed in 15 patients with RDA. Bone
mineral density was measured at the femoral neck and lumbar
spine (L1-L4) using dual-energy X-ray absorptiometry (Hologic).
For comparison, BMD was measured in 33 women with slowly
hip OA who were scheduled for primary total hip arthroplasty.
Comparisons between the two groups of patients were made
using student t test for all variables. Two-sided significance level
was fixed at 5%. All tests were made using SAS software version
9.13 (from SAS Institute).
Results: The patients with rapidly destructive hip OA (80%
women and 20%men) did not differ from control in age (74.9 ±
9.9 vs 74.7 ± 8.8; p=0.92) and BMI (26.3 ± 4.3 vs 26.3 ± 5;
p=0.96). In patients with RDA, mean BMD was 1.0 ±0.2 g/cm2
at the lumbar spine (Tscore: -0.6 ±1.3) and 0.7±0.1 g/cm2 at the
femoral neck (Tscore:-1.5±1.1). In controls, mean BMD was 1.0
±0.2 g/cm2 at the lumbar spine (Tscore: -0.8 ±1.5)(p=0.67) and
0.8±0.2 g/cm2 at the femoral neck (Tscore:-1.4±1.4)(p=0.40).
In three patients (20%), evidence of subchondral insufficiency
fracture was shown on MR imaging.
Conclusions: The results of our study do not support a role for
